Cipla launches generic Saxenda (liraglutide) in the U.S. via partner Orbicular's FDA approval. What this means for GLP-1 generics competition, payers, and Cipla's peptide strategy. Read
Cipla Limited (BSE: 500087 | NSE: CIPLA) has launched a generic version of Saxenda (liraglutide injection) in the United States, becoming one of a small number of pharmaceutical companies to offer ge… [+9581 chars]
